
Mansoor M Amiji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/560384/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overview of vaccine adjuvants. , 2022, , 9-25.		1
2	Systemic biodistribution and hepatocyte-specific gene editing with CRISPR/Cas9 using hyaluronic acid-based nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102488.	3.3	5
3	Application of nanotechnology in medical diagnosis and imaging. Current Opinion in Biotechnology, 2022, 74, 241-246.	6.6	33
4	Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets. Biomedicine and Pharmacotherapy, 2022, 149, 112812.	5.6	9
5	Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. Journal of Controlled Release, 2022, 345, 721-733.	9.9	25
6	Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer. Molecular Therapy - Oncolytics, 2022, 25, 57-68.	4.4	11
7	Cystatin SN is a potent upstream initiator of epithelial-derived type 2 inflammation in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2022, 150, 872-881.	2.9	19
8	Nucleic Acid Delivery for Endothelial Dysfunction in Cardiovascular Diseases. Methodist DeBakey Cardiovascular Journal, 2021, 12, 134.	1.0	5
9	Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 2021, 11, 1309-1315.	5.8	75
10	Role of vitronectin-rich protein corona on tumor-specific siRNA delivery and transfection with lipid nanoparticles. Nanomedicine, 2021, 16, 535-551.	3.3	13
11	Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. Journal of Controlled Release, 2021, 331, 176-186.	9.9	34
12	Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting. Frontiers in Pharmacology, 2021, 12, 660841.	3.5	6
13	Co-Silencing of Tissue Transglutaminase-2 and Interleukin-15 Genes in a Celiac Disease Mimetic Mouse Model Using a Nanoparticle-in-Microsphere Oral System. Molecular Pharmaceutics, 2021, 18, 3099-3107.	4.6	7
14	Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells, 2021, 10, 2204.	4.1	18
15	Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach. Biomaterials, 2021, 276, 120989.	11.4	15
16	Hyaluronic acid nanoparticle-encapsulated microRNA-125b repolarizes tumor-associated macrophages in pancreatic cancer. Nanomedicine, 2021, 16, 2291-2303.	3.3	14
17	Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102422.	3.3	11
18	In Vivo Labeling and Enumeration of Circulating Tumor Cells with a Folate-Receptor Targeted		0

Molecular Probe. , 2021, , .

#	Article	IF	CITATIONS
19	Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities. Nanomedicine, 2021, 16, 2651-2655.	3.3	5
20	BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia, 2020, 34, 210-223.	7.2	35
21	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. Regenerative Engineering and Translational Medicine, 2020, 6, 29-49.	2.9	16
22	Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes. Molecular Pharmaceutics, 2020, 17, 1996-2005.	4.6	70
23	Electrically Charged Biomaterials for Drug Delivery and Tissue Repair. Bioelectricity, 2020, 2, 67-67.	1.1	0
24	Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils. Drug Discovery Today, 2020, 25, 1013-1025.	6.4	4
25	Fluorescence Labeling of Circulating Tumor Cells with a Folate Receptor-Targeted Molecular Probe for Diffuse In Vivo Flow Cytometry. Molecular Imaging and Biology, 2020, 22, 1280-1289.	2.6	16
26	Protein Corona-Enabled Systemic Delivery and Targeting of Nanoparticles. AAPS Journal, 2020, 22, 83.	4.4	43
27	Pharmacokinetics and Biodistribution Analysis of Small Interference RNA for Silencing Tissue Transglutaminase-2 in Celiac Disease After Oral Administration in Mice Using Gelatin-Based Multicompartmental Delivery Systems. Bioelectricity, 2020, 2, 167-174.	1.1	5
28	The future of drug delivery in cancer treatment. , 2020, , 569-597.		1
29	Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Drug Delivery and Translational Research, 2020, 10, 766-790.	5.8	20
30	Technologies and Standardization in Research on Extracellular Vesicles. Trends in Biotechnology, 2020, 38, 1066-1098.	9.3	250
31	Delivery of neurotrophic factors in the treatment of age-related chronic neurodegenerative diseases. Expert Opinion on Drug Delivery, 2020, 17, 323-340.	5.0	14
32	Extracellular vesicle-mediated nucleic acid transfer and reprogramming in the tumor microenvironment. Cancer Letters, 2020, 482, 33-43.	7.2	17
33	Preparation of Hyaluronic Acid-Based Nanoparticles for Macrophage-Targeted MicroRNA Delivery and Transfection. Methods in Molecular Biology, 2020, 2118, 99-110.	0.9	4
34	The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation. Scientific Reports, 2019, 9, 11520.	3.3	23
35	Nanopillared Chitosan/Gelatin Films: A Biomimetic Approach for Improved Osteogenesis. ACS Biomaterials Science and Engineering, 2019, 5, 4311-4322.	5.2	20
36	Discriminant analysis followed by unsupervised cluster analysis including exosomal cystatins predict presence of chronic rhinosinusitis, phenotype, and disease severity. International Forum of Allergy and Rhinology, 2019, 9, 1069-1076.	2.8	16

#	Article	IF	CITATIONS
37	Challenging the CNS Targeting Potential of Systemically Administered Nanoemulsion Delivery Systems: a Case Study with Rapamycin-Containing Fish Oil Nanoemulsions in Mice. Pharmaceutical Research, 2019, 36, 134.	3.5	7
38	Local Immunomodulation Using an Adhesive Hydrogel Loaded with miRNA‣aden Nanoparticles Promotes Wound Healing. Small, 2019, 15, e1902232.	10.0	197
39	Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. Journal of Controlled Release, 2019, 309, 37-47.	9.9	74
40	On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635.	31.5	149
41	Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer. Cancer Letters, 2019, 461, 1-9.	7.2	44
42	Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 22, 102091.	3.3	7
43	Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine. Journal of Controlled Release, 2019, 316, 12-21.	9.9	13
44	Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development. Pharmaceutical Research, 2019, 36, 153.	3.5	39
45	The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for <i>in vivo</i> targeted delivery and transfection of oligonucleotides in murine tumor models. Nanoscale, 2019, 11, 18806-18824.	5.6	80
46	Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration. Journal of Controlled Release, 2019, 296, 140-149.	9.9	28
47	Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants. Journal of Controlled Release, 2019, 305, 29-40.	9.9	21
48	Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy. Expert Opinion on Biological Therapy, 2019, 19, 547-560.	3.1	6
49	Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration. Pharmaceutical Research, 2019, 36, 75.	3.5	10
50	The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. Nanoscale, 2019, 11, 8760-8775.	5.6	84
51	DHA-SBT-1214 Taxoid Nanoemulsion and Anti–PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Molecular Cancer Therapeutics, 2019, 18, 1961-1972.	4.1	14
52	Exosome swarms eliminate airway pathogens and provide passive epithelial immunoprotection through nitric oxide. Journal of Allergy and Clinical Immunology, 2019, 143, 1525-1535.e1.	2.9	42
53	CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 843-854.	2.5	16
54	Long-term drug delivery using implantable electrospun woven polymeric nanotextiles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 274-284.	3.3	33

#	Article	IF	CITATIONS
55	Optimization of the Conditions for Plasmid DNA Delivery and Transfection with Self-Assembled Hyaluronic Acid-Based Nanoparticles. Molecular Pharmaceutics, 2019, 16, 128-140.	4.6	30
56	Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opinion on Drug Delivery, 2018, 15, 481-494.	5.0	24
57	Raman Micro-spectral Imaging of Cells and Intracellular Drug Delivery Using Nanocarrier Systems. Springer Series in Surface Sciences, 2018, , 273-305.	0.3	4
58	Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery. Drug Discovery Today, 2018, 23, 519-533.	6.4	31
59	Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b. Nano Letters, 2018, 18, 3571-3579.	9.1	196
60	Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in NaÃ ⁻ ve and Tumor-Bearing Mice. Pharmaceutical Research, 2018, 35, 91.	3.5	11
61	Oral nucleic acid therapy using multicompartmental delivery systems. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1478.	6.1	15
62	Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting. PLoS ONE, 2018, 13, e0208122.	2.5	17
63	Combinatorial Approach in Rationale Design of Polymeric Nanomedicines for Cancer. , 2018, , 371-398.		1
64	Recent preclinical and clinical advances in oligonucleotide conjugates. Expert Opinion on Drug Delivery, 2018, 15, 629-640.	5.0	43
65	Exosome-Mediated Communication in the Tumor Microenvironment. , 2018, , 187-218.		3
66	Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma. Blood, 2018, 132, 3195-3195.	1.4	1
67	Facial Layer-by-Layer Engineering of Upconversion Nanoparticles for Gene Delivery: Near-Infrared-Initiated Fluorescence Resonance Energy Transfer Tracking and Overcoming Drug Resistance in Ovarian Cancer. ACS Applied Materials & Interfaces, 2017, 9, 7941-7949.	8.0	64
68	Therapeutic targeting strategies using endogenous cells and proteins. Journal of Controlled Release, 2017, 258, 81-94.	9.9	31
69	MicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells. Scientific Reports, 2017, 7, 3636.	3.3	28
70	Mathematical Modeling and Experimental Validation of Nanoemulsion-Based Drug Transport across Cellular Barriers. Pharmaceutical Research, 2017, 34, 1416-1427.	3.5	9
71	Plasma protein adsorption and biological identity of systemically administered nanoparticles. Nanomedicine, 2017, 12, 2113-2135.	3.3	76
72	Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an <i>in Vitro</i> Model of Celiac Disease. Molecular Pharmaceutics, 2017, 14, 3036-3044.	4.6	31

#	Article	IF	CITATIONS
73	Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth. Cancer Letters, 2017, 406, 71-80.	7.2	41
74	Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomaterialia, 2017, 47, 71-80.	8.3	94
75	Cancer stem cell-targeted therapeutics and delivery strategies. Expert Opinion on Drug Delivery, 2017, 14, 997-1008.	5.0	32
76	Molecular Imaging of Subclinical Diabetic Retinopathy. Journal of Ophthalmic and Vision Research, 2017, 12, 129-131.	1.0	1
77	Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Delivery, 2016, 23, 958-970.	5.7	49
78	Polymeric Nanoparticle-Based Photodynamic Therapy for Chronic Periodontitis in Vivo. International Journal of Molecular Sciences, 2016, 17, 769.	4.1	76
79	Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis. PLoS ONE, 2016, 11, e0147337.	2.5	22
80	Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opinion on Drug Delivery, 2016, 13, 987-998.	5.0	11
81	Biodegradable Polyester-Based Multi-Compartmental Delivery Systems for Oral Nucleic Acid Therapy. , 2016, , 417-443.		0
82	Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer. Pharmaceutical Research, 2016, 33, 2943-2953.	3.5	25
83	Peritoneal Macrophage-Specific TNF-α Gene Silencing in LPS-Induced Acute Inflammation Model Using CD44 Targeting Hyaluronic Acid Nanoparticles. Molecular Pharmaceutics, 2016, 13, 3404-3416.	4.6	27
84	Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems. Scientific Reports, 2016, 6, 30110.	3.3	136
85	Multifunctional combinatorial-designed nanoparticles for nucleic acid therapy. Proceedings of SPIE, 2016, , .	0.8	0
86	EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 589-600.	3.3	51
87	Delivery of enteric neural progenitors with 5-HT4 agonist-loaded nanoparticles and thermosensitive hydrogel enhances cell proliferation and differentiation following transplantation inÂvivo. Biomaterials, 2016, 88, 1-11.	11.4	43
88	Biodistribution and pharmacokinetics of <i>Mad2</i> siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. Nanomedicine, 2016, 11, 767-781.	3.3	51
89	Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles. Molecular Therapy, 2016, 24, 759-769.	8.2	48
90	Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 987-1002.	3.3	83

Mansoor M Amiji

#	Article	IF	CITATIONS
91	MicroRNA-223 Induced Repolarization of Peritoneal Macrophages Using CD44 Targeting Hyaluronic Acid Nanoparticles for Anti-Inflammatory Effects. PLoS ONE, 2016, 11, e0152024.	2.5	42
92	Redox-Responsive Nano-Delivery Systems for Cancer Therapy. Fundamental Biomedical Technologies, 2016, , 255-269.	0.2	0
93	Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles. Scientific Reports, 2015, 5, 16632.	3.3	96
94	Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. International Journal of Nanomedicine, 2015, 10, 2913.	6.7	29
95	Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis. International Journal of Nanomedicine, 2015, 10, 4405.	6.7	24
96	Cosilencing of <i>PKM-2</i> and <i>MDR-1</i> Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 1521-1531.	4.1	39
97	Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials, 2015, 61, 162-177.	11.4	187
98	The Development of Self-Emulsifying Oil-in-Water Emulsion Adjuvant and an Evaluation of the Impact of Droplet Size on Performance. Journal of Pharmaceutical Sciences, 2015, 104, 1352-1361.	3.3	39
99	Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharmaceutical Research, 2015, 32, 2097-2109.	3.5	75
100	Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases. AAPS Journal, 2015, 17, 813-827.	4.4	37
101	Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2071-2082.	3.3	28
102	Exosome mediated communication within the tumor microenvironment. Journal of Controlled Release, 2015, 219, 278-294.	9.9	576
103	Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. Molecular Pharmaceutics, 2015, 12, 1523-1533.	4.6	62
104	Image-Guided Delivery of Therapeutics to the Brain. Advances in Delivery Science and Technology, 2015, , 151-177.	0.4	1
105	MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Scientific Reports, 2015, 5, 8509.	3.3	109
106	EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharmaceutical Research, 2015, 32, 2753-63.	3.5	24
107	Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clinical Immunology, 2015, 160, 46-58.	3.2	148
108	Mitochondrial biology, targets, and drug delivery. Journal of Controlled Release, 2015, 207, 40-58.	9.9	125

#	Article	IF	CITATIONS
109	Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells. Molecular Pharmaceutics, 2015, 12, 4466-4477.	4.6	18
110	Near-infrared light activated delivery platform for cancer therapy. Advances in Colloid and Interface Science, 2015, 226, 123-137.	14.7	42
111	Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. Journal of Drug Targeting, 2015, 23, 605-618.	4.4	415
112	Providing Oligonucleotides with Steric Selectivity by Brush-Polymer-Assisted Compaction. Journal of the American Chemical Society, 2015, 137, 12466-12469.	13.7	81
113	Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opinion on Drug Delivery, 2015, 12, 393-414.	5.0	25
114	Abstract 352: Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. , 2015, , .		1
115	Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget, 2015, 6, 9313-9326.	1.8	107
116	Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance. Current Medicinal Chemistry, 2015, 22, 1335-1347.	2.4	23
117	Abstract 202: Four dimensional quantitative label-free holographic imaging of the cell cycle in tumor cell lines. , 2015, , .		0
118	Abstract LB-102: Layer-by-layer engineering of upconversion nanoparticle based siRNA and miRNA delivery system for cancer therapy. , 2015, , .		1
119	Abstract 2341: Characterization of macrophage behavior by 4-dimensional label free, quantitative holographic imaging. , 2015, , .		0
120	The impact of size on particulate vaccine adjuvants. Nanomedicine, 2014, 9, 2671-2681.	3.3	94
121	Multimodal Nano-Systems for Cancer Diagnosis, Imaging, and Therapy. Advances in Delivery Science and Technology, 2014, , 351-388.	0.4	0
122	Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. Journal of Controlled Release, 2014, 190, 515-530.	9.9	59
123	Novel RNA interference-based therapies for sepsis. Expert Opinion on Biological Therapy, 2014, 14, 419-435.	3.1	4
124	CNS Delivery and Pharmacokinetic Evaluations of DALDA Analgesic Peptide Analog Administered in Nano-Sized Oil-in-Water Emulsion Formulation. Pharmaceutical Research, 2014, 31, 1315-1324.	3.5	13
125	Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. BMC Cancer, 2014, 14, 75.	2.6	56
126	Nanoemulsions in Translational Research—Opportunities and Challenges in Targeted Cancer Therapy. AAPS PharmSciTech, 2014, 15, 694-708.	3.3	169

#	Article	IF	CITATIONS
127	Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. Journal of Controlled Release, 2014, 180, 117-124.	9.9	13
128	Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles after Vaginal Delivery in Mice. Pharmaceutical Research, 2014, 31, 1834-1845.	3.5	64
129	Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy. Journal of Materials Chemistry B, 2014, 2, 8069-8084.	5.8	52
130	<i>Mad2</i> Checkpoint Gene Silencing Using Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles in Non-Small Cell Lung Cancer Model. Molecular Pharmaceutics, 2014, 11, 3515-3527.	4.6	55
131	Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer. Pharmaceutical Research, 2014, 31, 2490-2502.	3.5	36
132	Analgesic Efficacy and Safety of DALDA Peptide Analog Delivery to the Brain Using Oil-in-Water Nanoemulsion Formulation. Pharmaceutical Research, 2014, 31, 2724-2734.	3.5	12
133	Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors. Molecular Pharmaceutics, 2014, 11, 2511-2526.	4.6	44
134	Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert Opinion on Biological Therapy, 2014, 14, 1145-1159.	3.1	43
135	Polymeric Nanosystems for Integrated Image-Guided Cancer Therapy. Frontiers in Nanobiomedical Research, 2014, , 199-233.	0.1	1
136	Nanotechnology Applications in Local Arterial Drug Delivery. Advances in Delivery Science and Technology, 2014, , 359-385.	0.4	0
137	Nano-Platforms for Tumor-Targeted Delivery of Nucleic Acid Therapies. Advances in Delivery Science and Technology, 2014, , 269-291.	0.4	0
138	Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for Nucleic Acid Therapy in the Gastrointestinal Tract. , 2014, , 283-312.		1
139	Abstract LB-13: Hyaluronic acid-based CD44 targeted nanoparticle delivery of combination MDR1 siRNA/paclitaxel to overcome drug resistance in ovarian cancer. Cancer Research, 2014, 74, LB-13-LB-13.	0.9	1
140	Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer. Molecular Therapy - Nucleic Acids, 2013, 2, e110.	5.1	113
141	Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems. International Journal of Pharmaceutics, 2013, 453, 400-407.	5.2	7
142	Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice. Molecular Pharmaceutics, 2013, 10, 2031-2044.	4.6	70
143	Role of integrated cancer nanomedicine in overcoming drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1784-1802.	13.7	288
144	Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study. Clinical Orthopaedics and Related Research, 2013, 471, 915-925.	1.5	37

#	Article	IF	CITATIONS
145	Engineering of an ω-3 polyunsaturated fatty acid-containing nanoemulsion system for combination C6-ceramide and 17β-estradiol delivery and bioactivity in human vascular endothelial and smooth muscle cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 885-894.	3.3	18
146	Multifunctional nanoparticles for targeting cancer and inflammatory diseases. Journal of Drug Targeting, 2013, 21, 888-903.	4.4	24
147	Label-free Raman microspectral analysis for comparison of cellular uptake and distribution between nontargeted and EGFR-targeted biodegradable polymeric nanoparticles. Drug Delivery and Translational Research, 2013, 3, 575-586.	5.8	20
148	Assessing the physical–chemical properties and stability of dapivirine-loaded polymeric nanoparticles. International Journal of Pharmaceutics, 2013, 456, 307-314.	5.2	42
149	Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials, 2013, 34, 3489-3502.	11.4	314
150	In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. Journal of Controlled Release, 2013, 172, 699-706.	9.9	128
151	Safety assessment of oral photodynamic therapy in rats. Lasers in Medical Science, 2013, 28, 479-486.	2.1	18
152	Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. International Journal of Pharmaceutics, 2013, 450, 278-289.	5.2	28
153	Nano-Sized Calcium Phosphate Particles for Periodontal Gene Therapy. Journal of Periodontology, 2013, 84, 117-125.	3.4	35
154	Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Delivery and Translational Research, 2013, 3, 336-351.	5.8	49
155	<i>In Vitro</i> and <i>Ex Vivo</i> Evaluation of Polymeric Nanoparticles for Vaginal and Rectal Delivery of the Anti-HIV Drug Dapivirine. Molecular Pharmaceutics, 2013, 10, 2793-2807.	4.6	74
156	Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Advanced Drug Delivery Reviews, 2013, 65, 891-901.	13.7	77
157	A Novel Use of Gentamicin in the ROS-Mediated Sensitization of NCI-H460 Lung Cancer Cells to Various Anticancer Agents. ACS Chemical Biology, 2013, 8, 2771-2777.	3.4	17
158	Anti-Angiogenic and Anti-Cancer Evaluation of Betulin Nanoemulsion in Chicken Chorioallantoic Membrane and Skin Carcinoma in Balb/c Mice. Journal of Biomedical Nanotechnology, 2013, 9, 577-589.	1.1	59
159	Fluorescence-guided optical coherence tomography imaging for colon cancer screening: a preliminary mouse study. Biomedical Optics Express, 2012, 3, 178.	2.9	64
160	Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin-Based Engineered Nanovectors. Journal of Visualized Experiments, 2012, , e3612.	0.3	21
161	Theranostic Applications of Plasmonic Nanosystems. ACS Symposium Series, 2012, , 383-413.	0.5	2
162	Phosphatidylinositol 3-kinase Inhibitor (PIK75) Containing Surface Functionalized Nanoemulsion for Enhanced Drug Delivery, Cytotoxicity and Pro-apoptotic Activity in Ovarian Cancer Cells. Pharmaceutical Research, 2012, 29, 2874-2886.	3.5	37

#	Article	IF	CITATIONS
163	Multi-Compartmental Vaccine Delivery System for Enhanced Immune Response to gp100 Peptide Antigen in Melanoma Immunotherapy. Pharmaceutical Research, 2012, 29, 3393-3403.	3.5	17
164	Interactions of Microbicide Nanoparticles with a Simulated Vaginal Fluid. Molecular Pharmaceutics, 2012, 9, 3347-3356.	4.6	65
165	Tuftsin-Modified Alginate Nanoparticles as a Noncondensing Macrophage-Targeted DNA Delivery System. Biomacromolecules, 2012, 13, 1074-1085.	5.4	67
166	Macrophage-Targeted Nanoparticle Delivery Systems. Nanostructure Science and Technology, 2012, , 47-83.	0.1	6
167	Synthesis and preliminary in vivo evaluations of polyurethane microstructures for transdermal drug delivery. Chemistry Central Journal, 2012, 6, 87.	2.6	12
168	Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 911, 76-83.	2.3	11
169	The antimicrobial activity of the appetite peptide hormone ghrelin. Peptides, 2012, 36, 151-156.	2.4	22
170	Multi-Compartmental Nanoparticles-in-Emulsion Formulation for Macrophage-Specific Anti-Inflammatory Gene Delivery. Pharmaceutical Research, 2012, 29, 1637-1649.	3.5	23
171	Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. Pharmaceutical Research, 2012, 29, 1468-1484.	3.5	74
172	Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. International Journal of Pharmaceutics, 2012, 427, 21-34.	5.2	49
173	Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2011, 2, e2.	2.5	61
174	Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells. Molecular Pharmaceutics, 2011, 8, 185-203.	4.6	132
175	Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opinion on Drug Delivery, 2011, 8, 1085-1104.	5.0	131
176	Combinatorial-Designed Multifunctional Polymeric Nanosystems for Tumor-Targeted Therapeutic Delivery. Accounts of Chemical Research, 2011, 44, 1009-1017.	15.6	110
177	Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer. PLoS ONE, 2011, 6, e24075.	2.5	82
178	Anti-Angiogenic Effects of Betulinic Acid Administered in Nanoemulsion Formulation Using Chorioallantoic Membrane Assay. Journal of Biomedical Nanotechnology, 2011, 7, 317-324.	1.1	60
179	Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. Journal of Controlled Release, 2011, 150, 77-86.	9.9	157
180	Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. Journal of Controlled Release, 2011, 155, 237-247.	9.9	112

#	Article	IF	CITATIONS
181	â€~Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics. Bioorganic and Medicinal Chemistry, 2011, 19, 6167-6173.	3.0	35
182	Nanoparticles: A Promising Modality in the Treatment of Sarcomas. Pharmaceutical Research, 2011, 28, 260-272.	3.5	15
183	Nanomedicine for Cancer Therapy. Pharmaceutical Research, 2011, 28, 181-186.	3.5	3
184	Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell International, 2011, 11, 3.	4.1	103
185	Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 389-399.	6.1	77
186	Photodynamic effects of methylene blue-loaded polymeric nanoparticles on dental plaque bacteria. Lasers in Surgery and Medicine, 2011, 43, 600-606.	2.1	92
187	Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 435-444.	3.3	106
188	Therapeutic strategies for endothelial dysfunction. Expert Opinion on Biological Therapy, 2011, 11, 1637-1654.	3.1	12
189	Polymeric Nanoparticles as Target-Specific Delivery Systems. , 2011, , 81-130.		Ο
190	<i>In vitro</i> and <i>In vivo</i> studies of local arterial gene delivery and transfection using lipopolyplexesâ€embedded stents. Journal of Biomedical Materials Research - Part A, 2010, 93A, 325-336.	4.0	14
191	Multifunctional Stimuli–Responsive Nanoparticles for Targeted Delivery of Small and Macromolecular Therapeutics. , 2010, , 555-585.		4
192	Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems. AAPS Journal, 2010, 12, 171-180.	4.4	51
193	Evaluation of the Factors Influencing Stomach-specific Delivery of Antibacterial Agents for Helicobacter pylori Infection. Journal of Pharmacy and Pharmacology, 2010, 51, 667-672.	2.4	82
194	Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices. Advanced Drug Delivery Reviews, 2010, 62, 305-315.	13.7	283
195	Nanotechnology solutions for infectious diseases in developing nations. Advanced Drug Delivery Reviews, 2010, 62, 375-377.	13.7	37
196	Nanotechnology solutions for mucosal immunization. Advanced Drug Delivery Reviews, 2010, 62, 394-407.	13.7	194
197	Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Advanced Drug Delivery Reviews, 2010, 62, 458-477.	13.7	179
198	A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Molecular Membrane Biology, 2010, 27, 260-273.	2.0	74

#	Article	IF	CITATIONS
199	Raman Micro-spectral Imaging of Cells and Intracellular Drug Delivery Using Nanocarrier Systems. Springer Series in Optical Sciences, 2010, , 137-163.	0.7	0
200	Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 167-172.	2.8	34
201	Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations. Journal of Pharmaceutical Sciences, 2010, 99, 1745-1761.	3.3	100
202	Curcumin Enhances Oral Bioavailability and Anti-Tumor Therapeutic Efficacy of Paclitaxel upon Administration in Nanoemulsion Formulation. Journal of Pharmaceutical Sciences, 2010, 99, 4630-4641.	3.3	106
203	Sustained Drug Release from Nonâ€eroding Nanoporous Templates. Small, 2010, 6, 213-216.	10.0	48
204	NON-CONDENSING POLYMERIC GENE DELIVERY SYSTEMS: PRINCIPLES AND APPLICATIONS. Nano LIFE, 2010, 01, 219-237.	0.9	2
205	Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8346-8351.	7.1	181
206	Preliminary evaluation of a nanotechnology-based approach for the more effective diagnosis of colon cancers. Nanomedicine, 2010, 5, 1467-1479.	3.3	17
207	Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. BioMedical Engineering OnLine, 2010, 9, 56.	2.7	37
208	Nanoparticle-based Endodontic Antimicrobial Photodynamic Therapy. Journal of Endodontics, 2010, 36, 322-328.	3.1	198
209	Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. PLoS ONE, 2010, 5, e10764.	2.5	128
210	Role of Eco-Friendly Strategies in the Development of Biomedical Nanotechnology. International Journal of Green Nanotechnology Biomedicine, 2009, 1, 9-23.	0.4	1
211	Delivery strategies to enhance mucosal vaccination. Expert Opinion on Biological Therapy, 2009, 9, 427-440.	3.1	40
212	Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer, 2009, 9, 399.	2.6	139
213	Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2009, 63, 711-722.	2.3	132
214	Label-Free Raman Spectral Imaging of Intracellular Delivery and Degradation of Polymeric Nanoparticle Systems. ACS Nano, 2009, 3, 3552-3559.	14.6	119
215	Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opinion on Drug Delivery, 2009, 6, 211-225.	5.0	112
216	Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells. Molecular Pharmaceutics, 2009, 6, 928-939.	4.6	416

#	Article	lF	CITATIONS
217	Enhancement in Anti-proliferative Effects of Paclitaxel in Aortic Smooth Muscle Cells upon Co-administration with Ceramide using Biodegradable Polymeric Nanoparticles. Pharmaceutical Research, 2008, 25, 1936-1947.	3.5	27
218	Cytotoxicity and Apoptosis Enhancement in Brain Tumor Cells Upon Coadministration of Paclitaxel and Ceramide in Nanoemulsion Formulations. Journal of Pharmaceutical Sciences, 2008, 97, 2745-2756.	3.3	105
219	A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. Biotechnology and Bioengineering, 2008, 101, 1072-1082.	3.3	24
220	Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. International Journal of Pharmaceutics, 2008, 347, 93-101.	5.2	242
221	Protein Nanospheres for Gene Delivery. Cold Spring Harbor Protocols, 2008, 2008, pdb.top30.	0.3	6
222	Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells. AAPS Journal, 2008, 10, 565-76.	4.4	69
223	Development of Novel Biodegradable Polymeric Nanoparticles-in-Microsphere Formulation for Local Plasmid DNA Delivery in the Gastrointestinal Tract. AAPS PharmSciTech, 2008, 9, 288-294.	3.3	92
224	Preparation and Loading of Gelatin Nanoparticles. Cold Spring Harbor Protocols, 2008, 2008, pdb.prot4885.	0.3	8
225	Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery. Fundamental Biomedical Technologies, 2008, , 33-66.	0.2	3
226	A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release, 2008, 126, 187-204.	9.9	1,981
227	Multi-functional nanocarriers for targeted delivery of drugs and genes. Journal of Controlled Release, 2008, 130, 121-128.	9.9	165
228	Poly(β-amino ester) and Cationic Phospholipid-Based Lipopolyplexes for Gene Delivery and Transfection in Human Aortic Endothelial and Smooth Muscle Cells. Biomacromolecules, 2008, 9, 1179-1187.	5.4	32
229	Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. Journal of Drug Targeting, 2008, 16, 302-310.	4.4	43
230	Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews, 2008, 34, 592-602.	7.7	381
231	Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model. Molecular Pharmaceutics, 2008, 5, 516-526.	4.6	127
232	Intracellular Trafficking Studies Using Gold-Encapsulated Gelatin Nanoparticles. Cold Spring Harbor Protocols, 2008, 2008, pdb.prot4886-pdb.prot4886.	0.3	2
233	Cell Transfection and Analysis Using DNA-Loaded Gelatin Nanoparticles. Cold Spring Harbor Protocols, 2008, 2008, pdb.prot4887-pdb.prot4887.	0.3	3
234	Therapeutic nanomedicine: Polymeric nanosystems for drug and gene delivery. European Journal of Nanomedicine, 2008, 1, .	0.6	0

#	Article	IF	CITATIONS
235	Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles. Clinical Cancer Research, 2008, 14, 3193-3203.	7.0	113
236	Multifunctional Magnetic Nanosystems for Tumor Imaging, Targeted Delivery, and Thermal Medicine. Fundamental Biomedical Technologies, 2008, , 381-408.	0.2	7
237	Raman microscopic imaging of cells and applications monitoring the uptake of drug delivery systems. Proceedings of SPIE, 2008, , .	0.8	4
238	Modulation of Intracellular Ceramide Using Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer. Cancer Research, 2007, 67, 4843-4850.	0.9	202
239	Nanocarriers for Systemic and Mucosal Vaccine Delivery. Recent Patents on Drug Delivery and Formulation, 2007, 1, 1-9.	2.1	52
240	Synthesis and Evaluation of Tripodal Peptide Analogues for Cellular Delivery of Phosphopeptides. Journal of Medicinal Chemistry, 2007, 50, 3604-3617.	6.4	37
241	Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opinion on Drug Delivery, 2007, 4, 197-213.	5.0	94
242	Nanotechnology-based delivery systems in HIV/AIDS therapy. Future HIV Therapy, 2007, 1, 49-59.	0.4	19
243	Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. International Journal of Cancer, 2007, 121, 1830-1838.	5.1	103
244	Biodistribution and Pharmacokinetic Analysis of Long-Circulating Thiolated Gelatin Nanoparticles Following Systemic Administration in Breast Cancer-Bearing Mice. Journal of Pharmaceutical Sciences, 2007, 96, 397-407.	3.3	121
245	Role of Nanotechnology in Pharmaceutical Product Development. Journal of Pharmaceutical Sciences, 2007, 96, 2547-2565.	3.3	181
246	Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). Journal of Controlled Release, 2007, 119, 339-348.	9.9	147
247	Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology, 2007, 59, 477-484.	2.3	141
248	Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery. Pharmaceutical Research, 2007, 24, 1405-1414.	3.5	584
249	Poly(ethylene glycol)–modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 32-42.	3.3	130
250	An Overview of Condensing and Noncondensing Polymeric Systems for Gene Delivery. Cold Spring Harbor Protocols, 2007, 2007, pdb.top9-pdb.top9.	0.3	1
251	Nanoparticulate carriers for the treatment of coronary restenosis. International Journal of Nanomedicine, 2007, 2, 143-61.	6.7	23
252	Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opinion on Drug Delivery, 2006, 3, 205-216.	5.0	317

#	Article	IF	CITATIONS
253	Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opinion on Drug Delivery, 2006, 3, 613-628.	5.0	88
254	Long-Circulating Polymeric Nanoparticles for Drug and Gene Delivery to Tumors. , 2006, , 231-242.		2
255	Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS. Pharmaceutical Research, 2006, 23, 2638-2645.	3.5	137
256	Tetracycline-containing Chitosan Microspheres for Local Treatment of Helicobacter pylori Infection. Cellulose, 2006, 14, 3-14.	4.9	15
257	Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. Journal of Controlled Release, 2006, 110, 422-430.	9.9	121
258	Improved Oral Delivery of Paclitaxel Following Administration in Nanoemulsion Formulations. Journal of Nanoscience and Nanotechnology, 2006, 6, 3215-3221.	0.9	115
259	A Review of Nanocarrier-Based CNS Delivery Systems. Current Drug Delivery, 2006, 3, 219-232.	1.6	187
260	Polymeric Nanoparticles for Delivery in the Gastro-Intestinal Tract. , 2006, , 609-648.		6
261	Preparation and In Vitro Characterization of Multifunctional Nanoemulsions for Simultaneous MR Imaging and Targeted Drug Delivery. Journal of Biomedical Nanotechnology, 2006, 2, 217-224.	1.1	49
262	Formulation and Physiological Factors Influencing CNS Delivery upon Intranasal Administration. Critical Reviews in Therapeutic Drug Carrier Systems, 2006, 23, 319-347.	2.2	27
263	Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. International Journal of Nanomedicine, 2006, 1, 51-58.	6.7	190
264	Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discovery Medicine, 2006, 6, 157-62.	0.5	34
265	Poly(ethylene oxide)-modified poly(É>-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. International Journal of Pharmaceutics, 2005, 293, 261-270.	5.2	322
266	An approach to heterobifunctional poly(ethyleneglycol) bioconjugates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5558-5561.	2.2	13
267	Preparation and Evaluation of Thiol-Modified Gelatin Nanoparticles for Intracellular DNA Delivery in Response to Glutathione. Bioconjugate Chemistry, 2005, 16, 1423-1432.	3.6	187
268	Cellular Interactions and In Vitro DNA Transfection Studies with Poly(ethylene glycol)â€Modified Gelatin Nanoparticles. Journal of Pharmaceutical Sciences, 2005, 94, 184-198.	3.3	70
269	Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies. Pharmaceutical Research, 2005, 22, 951-961.	3.5	194
270	Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies. Pharmaceutical Research, 2005, 22, 2107-2114.	3.5	238

Mansoor M Amiji

#	Article	IF	CITATIONS
271	Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery. Technology in Cancer Research and Treatment, 2005, 4, 615-625.	1.9	116
272	Poly(ethylene oxide)-Modified Poly(β-amino ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs. 1. In Vitro Evaluations. Molecular Pharmaceutics, 2005, 2, 357-366.	4.6	173
273	Biomedical Applications of Gold Nanoparticles Functionalized Using Hetero-Bifunctional Poly(ethylene glycol) Spacer. Materials Research Society Symposia Proceedings, 2004, 845, 199.	0.1	12
274	Biodegradable Polymeric Nanoparticles for Tumor-Selective Tamoxifen Delivery: <i>In Vitro and in Vivo</i> Studies. Materials Research Society Symposia Proceedings, 2004, 845, 228.	0.1	1
275	Biodistribution and Tumor-Targeting Potential of Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles. Materials Research Society Symposia Proceedings, 2004, 845, 233.	0.1	1
276	Stomach-specific anti-H. pylori therapy. International Journal of Pharmaceutics, 2004, 272, 99-108.	5.2	54
277	Enzyme immobilization in novel alginate–chitosan core-shell microcapsules. Biomaterials, 2004, 25, 1937-1945.	11.4	275
278	Biodistribution and Targeting Potential of Poly(ethylene glycol)-modified Gelatin Nanoparticles in Subcutaneous Murine Tumor Model. Journal of Drug Targeting, 2004, 12, 585-591.	4.4	149
279	Poly-N-Acetyl Glucosamine–Mediated Red Blood Cell Interactions. Journal of Trauma, 2004, 57, S7-S12.	2.3	30
280	Targeted Drug Delivery to Tumor Cells Using Colloidal Carriers. , 2004, , 181-215.		4
281	Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles. AAPS PharmSci, 2003, 5, 28-34.	1.3	73
282	Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. Journal of Controlled Release, 2003, 86, 223-234.	9.9	197
283	Chitosan-based gastrointestinal delivery systems. Journal of Controlled Release, 2003, 89, 151-165.	9.9	761
284	Stomach-Specific Anti-H. pyloriTherapy. II. Gastric Residence Studies of Tetracycline-Loaded Chitosan Microspheres in Gerbils. Pharmaceutical Development and Technology, 2003, 8, 253-262.	2.4	46
285	Polymeric Gene Delivery Systems. , 2003, , .		1
286	Intratumoral Administration of Paclitaxel in an In Situ Gelling Poloxamer 407 Formulation. Pharmaceutical Development and Technology, 2002, 7, 195-202.	2.4	62
287	Stomach-specific anti-H. pylori therapy. I: preparation and characterization of tetracyline-loaded chitosan microspheres. International Journal of Pharmaceutics, 2002, 235, 87-94.	5.2	128
288	Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations. Biomaterials, 2002, 23, 2723-2731.	11.4	93

#	Article	IF	CITATIONS
289	Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. International Journal of Pharmaceutics, 2002, 249, 127-138.	5.2	457
290	Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharmaceutical Research, 2002, 19, 1061-1067.	3.5	250
291	Evaluation of the permeability and blood-compatibility properties of membranes formed by physical interpenetration of chitosan with PEO/PPO/PEO triblock copolymers. Journal of Applied Polymer Science, 2001, 80, 1274-1284.	2.6	16
292	pH-Responsive Polymer Microspheres: Rapid Release of Encapsulated Material within the Range of Intracellular pH. Angewandte Chemie - International Edition, 2001, 40, 1707-1710.	13.8	245
293	Intracellular pH Financial support was provided by the NSF (Cooperative Agreement No. ECC9843342 to) Tj ETQo Army (Cooperative Agreement DAMD 17-99-2-9-001 to the Center for Innovative Minimally Invasive) Tj ETQq1 1 (
294	Chitosan—Pluronic Physical Interpenetrating Network: Membrane Fabrication and Protein Permeability Studies. ACS Symposium Series, 1999, , 178-186.	0.5	1
295	Platelet adhesion and activation on an amphoteric chitosan derivative bearing sulfonate groups. Colloids and Surfaces B: Biointerfaces, 1998, 10, 263-271.	5.0	70
296	Gelatin-Poly(Ethylene Oxide) Semi-interpenetrating Polymer Network with pH-Sensitive Swelling and Enzyme-Degradable Properties for Oral Drug Delivery. Drug Development and Industrial Pharmacy, 1997, 23, 575-582.	2.0	27
297	Surface modification of chitosan membranes by complexation-interpenetration of anionic polysaccharides for improved blood compatibility in hemodialysis. Journal of Biomaterials Science, Polymer Edition, 1997, 8, 281-298.	3.5	73
298	Synthesis of anionic poly(ethylene glycol) derivative for chitosan surface modification in blood-contacting applications. Carbohydrate Polymers, 1997, 32, 193-199.	10.2	93
299	Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Pharmaceutical Research, 1996, 13, 588-593.	3.5	343
300	pH-Sensitive Swelling and Drug-Release Properties of Chitosan—Poly(ethylene oxide) Semi-interpenetrating Polymer Network. ACS Symposium Series, 1996, , 209-220.	0.5	8
301	Permeability and blood compatibility properties of chitosan-poly(ethylene oxide) blend membranes for haemodialysis. Biomaterials, 1995, 16, 593-599.	11.4	142
302	Pyrene fluorescence study of chitosan self-association in aqueous solution. Carbohydrate Polymers, 1995, 26, 211-213.	10.2	157
303	Photophysical Characterization of Insulin Denaturation and Aggregation at Hydrophobic Interfaces. Drug Development and Industrial Pharmacy, 1995, 21, 1661-1669.	2.0	1
304	Analysis on the surface adsorption of PEO/PPO/PEO triblock copolymers by radiolabelling and fluorescence techniques. Journal of Applied Polymer Science, 1994, 52, 539-544.	2.6	37
305	Surface Modification by Radiation-Induced Grafting of PEO/PPO/PEO Triblock Copolymers. Journal of Colloid and Interface Science, 1993, 155, 251-255.	9.4	34
306	Hydrogel delivery systems for vaginal and oral applications. Advanced Drug Delivery Reviews, 1993, 11, 137-167.	13.7	79

#	Article	IF	CITATIONS
307	Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity. Journal of Biomaterials Science, Polymer Edition, 1993, 4, 217-234.	3.5	315
308	Surface Modification of Polymeric Biomaterials with Poly(ethylene oxide). ACS Symposium Series, 1993, , 135-146.	0.5	18
309	Study on the prevention of surface-induced platelet activation by albumin coating. Journal of Biomaterials Science, Polymer Edition, 1992, 3, 375-388.	3.5	68
310	Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. Biomaterials, 1992, 13, 682-692.	11.4	339